<DOC>
	<DOCNO>NCT02640222</DOCNO>
	<brief_summary>The purpose study evaluate APIXABAN use Prevention Stroke Systemic Embolism Patients Atrial Fibrillation Real-Life Setting France , data SNIIRAM ( French data base ) .</brief_summary>
	<brief_title>APIXABAN Prevention Stroke Systemic Embolism Patients With Atrial Fibrillation Real-Life Setting France SNIIRAM Study</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Patient meeting inclusion criterion French Système national d'information interrégimes de l'assurance maladie ( SNIIRAM ) /Programme de médicalisation de systèmes d'information ( PMSI ) claim database ( Patient insure French national health insurance general scheme stricto sensu ( apart local mutualist section ) Patients least one reimbursement AC treatment ( acenocoumarol , warfarine fluidione VKA treatment , apixaban , dabigatran rivaroxaban New oral anticoagulant ( NOACs ) ) treatment inclusion period Patients initiate new AC treatment inclusion period , either AC naive Patients age 18 old first anticoagulant initiation inclusion period Patient diagnose nonvalvular Atrial fibrillation ( AF )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>